Technical Snapshots for These Medical Supplies Stocks -- Microbot Medical, C.R. Bard, Cooper Cos., and Waters

Tuesday, November 14, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 14, 2017 /PRNewswire/ -- If you want a Stock Review on MBOT, BCR, COO, or WAT then come over to

and sign up for your free customized report. has redirected investors' attention to the Medical Instruments and Supplies Manufacturing industry, which primarily researches, develops, and produces nonelectronic medical, surgical,
dental, and veterinary instruments. In this morning's line-up are: Microbot Medical Inc. (NASDAQ: MBOT), C. R. Bard Inc. (NYSE: BCR), The Cooper Cos. Inc. (NYSE: COO), and Waters Corp. (NYSE: WAT). Access's complimentary reports for today's stocks line-up at:

Microbot MedicalShares in Yokneam, Israel-based Microbot Medical Inc. saw a drop of 2.73%, ending Monday's trading session at $1.07. The stock recorded a trading volume of 477,736 shares. The Company's shares are trading 8.92% below their 50-day moving average. Moreover, shares of Microbot Medical, which engages in the research, design, development, and commercialization of micro-robotics medical technologies, have a Relative Strength Index (RSI) of 42.48.  

On November 08th, 2017, Microbot Medical has been awarded an additional non-dilutive grant of up to 2,610,000 Israeli New Shekels (approximately $735,000) from the Israel Innovation Authority of Israel's Ministry of Economy. The grant provides additional sources to be utilized by the Company for the continued development of its Self-Cleaning Shunt for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. Visit us today and access your complete report on MBOT for free at:

C.R. BardMurray Hill, New Jersey headquartered C.R. Bard Inc.'s stock climbed 0.36%, closing the day at $333.08 with a total trading volume of 319,747 shares. The Company's shares have advanced 3.00% in the past month, 3.82% in the previous three months, and 48.26% since the start of this year. The stock is trading 2.75% and 12.08% above its 50-day and 200-day moving averages, respectively. Additionally, shares of C.R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 62.14. 

On October 25th, 2017, C.R. Bard reported Q3 2017 financial results. Net sales for Q3 2017 were $989.8 million, net income was $94.1 million, and diluted earnings per share were $1.25. In conjunction with the quarterly results, the Company has increased its full year 2017 net sales of between 5.5% and 6% on an as-reported basis. Full year 2017 diluted earnings per share are projected to be between $11.85 and $11.90. The complimentary research report on BCR can be accessed at:

Cooper Cos.On Monday, shares in Pleasanton, California headquartered The Cooper Cos. Inc. recorded a trading volume of 366,420 shares. The stock ended the day 3.50% higher at $237.07. The Company's shares have advanced 0.45% in the past month and 35.52% on an YTD basis. The stock is trading above its 200-day moving average by 6.02%. Furthermore, shares of Cooper Cos., which operates as a medical device company worldwide, have an RSI of 51.73.  

On November 01st, 2017, Cooper Cos. (COO) announced the completion of its previously announced purchase of the assets and global rights and business of the PARAGARD® Intrauterine Device from Teva Pharmaceutical Industries Ltd. for a purchase price of approximately $1.1 billion. COO reconfirmed that it expects the transaction to be accretive to earnings per share, excluding acquisition and integration related expenses and deal-related amortization, by approximately $0.70 to $0.75 in year one while generating mid-single digit revenue growth. Register for free on and download the research report on COO at:

WatersMilford, Massachusetts-based Waters Corp.'s stock climbed 0.74%, finishing yesterday's session at $194.64 with a total trading volume of 352,045 shares. The Company's shares have advanced 4.76% in the last one month, 8.42% in the previous three months, and 44.83% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.85% and 11.90%, respectively. Additionally, shares of Waters, which operates as an analytical instrument manufacturer in the US and internationally, have an RSI of 55.81.  

On October 19th, 2017, Waters announced that Douglas A. Berthiaume will retire as Chairman of the Board of Directors of the Company, effective December 31st, 2017. The Board has elected Christopher J. O'Connell, President and CEO, as its new Chairman, effective January 01st, 2018. Thomas P. Salice will continue to serve as the Company's Independent Lead Director. Get free access to your research report on WAT at:

Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES: The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTYDST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERINGThis document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: Phone number:  (207)331-3313Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

View original content:



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store